RedHill Biopharma (RDHL) Short term Debt (2020 - 2022)

RedHill Biopharma (RDHL) has 3 years of Short term Debt data on file, last reported at $115.2 million in Q4 2022.

• Short term Debt for Q4 2022 came in at $115.2 million, up 37.79% year-over-year; the trailing twelve-month figure through Dec 2022 was $115.2 million (up 37.79% YoY), and the FY2022 annual result was $115.2 million, up 37.79% from the prior year.
• Short term Debt improved to $115.2 million in Q4 2022 per RDHL's latest filing, from $113.9 million in the prior quarter.
• Over five years, Short term Debt peaked at $115.2 million in Q4 2022 and troughed at $78.2 million in Q1 2020.
• A 3-year average of $87.7 million and a median of $83.3 million in 2021 frame the typical range for Short term Debt.
• The sharpest annual moves came in 2021 and 2022: Short term Debt grew 2.74% in 2021, then surged 37.79% in 2022.
• A 3-year view of Short term Debt shows it stood at $81.4 million in 2020, then advanced by 2.74% to $83.6 million in 2021, then jumped by 37.79% to $115.2 million in 2022.
• Business Quant data shows RDHL's Short term Debt at $115.2 million in Q4 2022, $113.9 million in Q3 2022, and $85.5 million in Q2 2022.